Table 1.
Demographic and clinical data for 461 patients at each stage of CKD
| Variable | Stage 3(n = 189; 41.0%) | Stage 4(n = 144; 31.2%) | Stage 5(n = 128; 27.8%) | P |
|---|---|---|---|---|
| Age (years) | 65 (56 to 74) | 69 (60 to 76) | 67 (58 to 77) | 0.056 |
| Male (%) | 69.3 | 67.4 | 44.5a,b | <0.001 |
| eGFR (ml/min per 1.73 m2) | 43.6 (36.1 to 51.7) | 22.0 (17.9 to 26.1) | 9.7 (7.2 to 12.2) | N/A |
| Overt proteinuria (%)c | 37.6 | 62.7a | 80.3a,b | <0.001 |
| Hemoglobin (g/dl) | 12.9 (11.5 to 14.3) | 10.9 (9.8 to 12.1)a | 9.6 (8.8 to 10.4)a,b | <0.001 |
| Diabetes (%) | 31.8 | 41.7 | 39.1 | 0.148 |
| Hypertension (%) | 76.7 | 92.4a | 95.3a | <0.001 |
| Prior CVD (%) | 20.1 | 31.3 | 26.6 | 0.064 |
| Smoking history (%)c | 45.7 | 48.9 | 39.7 | 0.308 |
| RAS inhibitor (%) | 59.3 | 63.9 | 47.7b | 0.021 |
Continuous and categorical values are presented as median (interquartile range) and percentage of total, respectively. P values were adjusted by the method of Holm in multiple testing. Pt, patients; RAS, renin-angiotensin system; N/A, not applicable.
a
Significant difference versus stage 3 CKD.
b
Significant difference versus stage 4 CKD.
c
n = 453 due to missing data.